![Jean-Marc Le Doussal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Marc Le Doussal
Fondateur chez
Remora Capital SA
Profil
Jean-Marc Le Doussal is the founder of Remora Capital SA, serving as Managing Partner since 2012, founded in 2009.
Mr. Le Doussal is the founder of Activen SA, serving as Chairman since 2011, founded in 2010.
Le Doussal is the founder of OGD2 Pharma SAS, serving as President since 2014, founded in 2014.
Former job includes Chairman at Telix Pharmaceuticals SAS.
Postes actifs de Jean-Marc Le Doussal
| Sociétés | Poste | Début |
|---|---|---|
Remora Capital SA
 Remora Capital SA Investment ManagersFinance Remora Capital invests in companies located in Switzerland & France. The firm focuses on immuno-oncology, aging and e-health sectors. They provide financing for early & growth stage transactions. Its investment size ranges from CHF 0.5 - 3 million. It acts as lead investor. | Fondateur | 22/09/2009 |
OGD2 Pharma SAS
 OGD2 Pharma SAS BiotechnologyHealth Technology Develops and commercializes anti-GD2 cancer immunotherapies that target O-acetylated-GD2 | Fondateur | 28/10/2014 |
Activen SA
 Activen SA Chemicals: SpecialtyProcess Industries Develops active molecules for the cosmetic industry | Fondateur | 01/01/2010 |
Anciens postes connus de Jean-Marc Le Doussal
| Sociétés | Poste | Fin |
|---|---|---|
Telix Pharmaceuticals SAS
 Telix Pharmaceuticals SAS BiotechnologyHealth Technology Develops anti-cancer radiopharmaceuticals based on monoclonal antibodies | Président | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Remora Capital SA
Remora Capital SA Investment ManagersFinance Remora Capital invests in companies located in Switzerland & France. The firm focuses on immuno-oncology, aging and e-health sectors. They provide financing for early & growth stage transactions. Its investment size ranges from CHF 0.5 - 3 million. It acts as lead investor. | Finance |
Activen SA
Activen SA Chemicals: SpecialtyProcess Industries Develops active molecules for the cosmetic industry | Process Industries |
Telix Pharmaceuticals SAS
Telix Pharmaceuticals SAS BiotechnologyHealth Technology Develops anti-cancer radiopharmaceuticals based on monoclonal antibodies | Health Technology |
OGD2 Pharma SAS
OGD2 Pharma SAS BiotechnologyHealth Technology Develops and commercializes anti-GD2 cancer immunotherapies that target O-acetylated-GD2 | Health Technology |
